跳至主要内容
临床试验/NCT02154854
NCT02154854Unknown4 期

Effect of Advagraf on Arterial Stiffness and on Vascular Fibrosis Plasma Markers on de Novo Renal Transplant Patients

University Hospital, Tours11 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
104
试验地点
11
主要终点
Aorta stiffness at one year post-tranplantation

研究概览

简要总结

The purpose of this study is to compare parallel-group effects between 4 months and 12 months post-transplantation 2 values of target residual concentrations of Advagraf on vascular parameters in de novo renal transplant patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 et 70 years
  • Patient accepting to give a written informed consent
  • Recipients of a first renal allograft (deceased or living, non HLA identical donor with compatible ABO blood type)
  • Randomized in the ADEQUATE study
  • Patients must have at J112 +/- 3 days a stable renal function (MDRD 4) with an absence of DSA since transplantation.
  • Negative T cross-match in cytotoxicity
  • Tolerate a daily dose of MMF at 1g

排除标准

  • Acute rejection during the first months
  • Existence of a BK infection since M3
  • Proteinuria/reatininuria ratio > 1g/g since M3

研究组 & 干预措施

Group A - tacrolimus half-dose

Experimental

Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.

Drug: Tacrolimus targeted half-dose

干预措施: Tacrolimus targeted half-dose (Drug)

Group B - tacrolimus unchanged dose

Experimental

Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose

干预措施: Tacrolimus targeted plain dose (Drug)

结局指标

主要结局

Aorta stiffness at one year post-tranplantation

时间窗: 12 months

Evaluate the aorta stiffness at 1 year post-renal transplantation and its evolution in patients who received a half reduction of their daily dose of Advagraf ® 4 months after transplantation compared with patients whose dose has not been divided.

次要结局

  • Endothelial activation at one year post-tranplantation(12 months)
  • Blood pressure(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验